ProCE Banner Activity

Preliminary Phase I/II Results of Venetoclax/Dara/Dex vs Bortezomib/Dara/Dex in t(11;14) Relapsed/Refractory Multiple Myeloma

Slideset Download
Conference Coverage
In patients with t(11;14) R/R MM, venetoclax/daratumumab/dexamethasone appears safe with promising efficacy vs bortezomib/daratumumab/dexamethasone.

Released: December 17, 2021

Expiration: December 16, 2022

Share

Provided by

Provided by Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by educational grants from

AbbVie

AstraZeneca

Daiichi Sankyo, Inc.

GlaxoSmithKline

Incyte Corporation

Jazz Pharmaceuticals, Inc.

Merck Sharp & Dohme Corp.

Novartis Pharmaceuticals Corporation